REAL-WORLD EVIDENCE IN DRUG DEVELOPMENT AND EVALUATION
ebook

REAL-WORLD EVIDENCE IN DRUG DEVELOPMENT AND EVALUATION (ebook)

HARRY YANG

$1,100.00
IVA incluido
Editorial:
CHAPMAN & HALL
Materia
MEDICINA GRAL
ISBN:
9780429676819
Formato:
Epublication content package
Idioma:
Inglés
DRM
Si

Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field. Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions. Features Provides the first book and a single source of information on RWE in drug development Covers a broad array of topics on outcomes- and value-based RWE assessments Demonstrates proper Bayesian application and causal inference for real-world data (RWD) Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise

Otros libros del autor

  • DATA SCIENCE, AI, AND MACHINE LEARNING IN DRUG DEVELOPMENT
    HARRY YANG
    The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven ...

    $1,480.00

  • EMERGING NON-CLINICAL BIOSTATISTICS IN BIOPHARMACEUTICAL DEVELOPMENT AND MANUFACTURING
    HARRY YANG
    The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-d...

    $1,380.00